Peptide-drug conjugates (PDCs) represent a cutting-edge frontier in oncology therapeutics, combining the specificity of peptides with the potent cell-killing power of cytotoxic agents.
Peptide-drug conjugates (PDCs) represent a cutting-edge frontier in oncology therapeutics, combining the specificity of peptides with the potent cell-killing power of cytotoxic agents.
“Position 4” didn’t seem important until researchers took a long look at a particular peptide. That part of the peptide drawn from a SARS-CoV virus turned out to have an unexpected but significant influence on how it stably binds with a receptor central to the immune system’s ability to attack diseased cells. In a study […]